Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity.

Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, Corbin JD.

J Biol Chem. 2002 Dec 6;277(49):47581-7. Epub 2002 Sep 30.

2.

Allosteric sites of phosphodiesterase-5 sequester cyclic GMP.

Kotera J, Francis SH, Grimes KA, Rouse A, Blount MA, Corbin JD.

Front Biosci. 2004 Jan 1;9:378-86.

PMID:
14766375
3.

Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation.

Zoraghi R, Bessay EP, Corbin JD, Francis SH.

J Biol Chem. 2005 Mar 25;280(12):12051-63. Epub 2005 Jan 27.

4.

Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase.

Liu L, Underwood T, Li H, Pamukcu R, Thompson WJ.

Cell Signal. 2002 Jan;14(1):45-51.

PMID:
11747988
5.
6.

Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.

Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD.

Mol Pharmacol. 2004 Jul;66(1):144-52.

7.

Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.

Turko IV, Ballard SA, Francis SH, Corbin JD.

Mol Pharmacol. 1999 Jul;56(1):124-30.

8.
9.

Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil.

Bessay EP, Blount MA, Zoraghi R, Beasley A, Grimes KA, Francis SH, Corbin JD.

J Pharmacol Exp Ther. 2008 Apr;325(1):62-8. doi: 10.1124/jpet.107.133405. Epub 2008 Jan 16.

10.

[3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.

Corbin JD, Blount MA, Weeks JL 2nd, Beasley A, Kuhn KP, Ho YS, Saidi LF, Hurley JH, Kotera J, Francis SH.

Mol Pharmacol. 2003 Jun;63(6):1364-72.

11.
13.

Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5).

Fink TL, Francis SH, Beasley A, Grimes KA, Corbin JD.

J Biol Chem. 1999 Dec 3;274(49):34613-20.

14.

Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.

Bessay EP, Zoraghi R, Blount MA, Grimes KA, Beasley A, Francis SH, Corbin JD.

Front Biosci. 2007 Jan 1;12:1899-910.

PMID:
17127429
15.
16.

Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP.

Okada D, Asakawa S.

Biochemistry. 2002 Jul 30;41(30):9672-9.

PMID:
12135389
17.

Probing domain functions of chimeric PDE6alpha'/PDE5 cGMP-phosphodiesterase.

Granovsky AE, Natochin M, McEntaffer RL, Haik TL, Francis SH, Corbin JD, Artemyev NO.

J Biol Chem. 1998 Sep 18;273(38):24485-90.

18.

Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.

Corbin JD, Francis SH.

Cell Signal. 2011 Oct;23(10):1578-83. doi: 10.1016/j.cellsig.2011.05.005. Epub 2011 May 17.

PMID:
21620965
20.

Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.

Weeks JL, Blount MA, Beasley A, Zoraghi R, Thomas MK, Sekhar KR, Corbin JD, Francis SH.

Methods Mol Biol. 2005;307:239-62.

PMID:
15988068

Supplemental Content

Support Center